Drug Profile
TAK 361S
Alternative Names: DTaP/TAK-361S quadruple vaccine - Takeda; Quadruple vaccine including Sabin-IPV - Takeda; Sabin-IPV-containing vaccines - Takeda/Japan Poliomyelitis Research Institute; TAK361SLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Takeda
- Class Bacterial vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Diphtheria; Pertussis; Poliomyelitis; Tetanus
Most Recent Events
- 02 Feb 2015 Discontinued - Phase-II for Diphtheria (Combination therapy, Prevention) in Japan (Parenteral)
- 02 Feb 2015 Discontinued - Phase-II for Pertussis (Combination therapy, Prevention) in Japan (Parenteral)
- 02 Feb 2015 Discontinued - Phase-II for Poliomyelitis (Combination therapy, Prevention) in Japan (Parenteral)